Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q4 | Jan 15, 2026 | ClearBridge Investments Small Cap Growth Strategy | 0.0% | 0.0% | BE, BETA, BHVN, DUOL, DYN, ELF, GKOS, IBP, INSM, LRN, NVS, PEN, PTGX, QLYS, RBC, SGRY, SSD, TREX, VRNS, WIX | active management, AI, Biotechnology, Capital markets, earnings, growth, small cap, Valuations | The manager expects 2026 could mark a period where productivity and monetization benefits of AI become more visible across industries. Several holdings are actively leveraging AI to improve efficiency, offer new products, or provide solutions to secure and manage critical data that AI utilizes. Biotech sector rebounded strongly behind positive clinical and commercial outcomes, healthy M&A activity, performance mean reversion and lower interest rates. The Russell 2000 Growth Biotech Index returned 28.1% in Q4, with the manager adding modestly to relative performance despite benchmark biotech constituents being up over 40% for the year. Capital markets appear to be accelerating with IPO activity improving after a multiyear lull and M&A volumes rebounding. This environment is historically favorable to the strategy, with recent transactions highlighting sophisticated buyers deploying capital at depressed valuations. Small cap earnings growth is forecasted to handily exceed large caps in 2026, with the third quarter marking the first time in over a decade that small caps exceeded large caps in earnings growth. The manager believes the asset class is poised for stronger performance with relative valuations still at attractive levels. | SIMP PTGX |
View |
| 2025 Q4 | Jan 15, 2026 | RTW Investments | 15.5% | 35.7% | ALNY, ARGX, AVID, DYN, IMTX, INSM, MDGL, PTCT, RCKT, STOK, TARS, UCB, URGN | Biotechnology, Drug Discovery, Gene Therapy, healthcare, M&A, Pharmaceuticals, Rare Diseases | The sector saw $105B in M&A activity, more than double the prior year and fourth highest in the last decade. Combined with a friendlier FTC, pharmas had enough policy clarity to pursue larger deals by fall. The recovery is likely still in early innings with continued M&A expected. After four years of underperformance, biotech indices finished ahead with NBI +32.4% and R2kB +44.6%. The bear market that endured over four consecutive years ended, with major biotech indices outperforming both the S&P 500 and Nasdaq. AI tools and lower cost Chinese R&D are mega-trends that should materially increase drug discovery productivity. The portfolio includes significant exposure to rare disease therapeutics, with companies like PTC Therapeutics developing medicines for rare neurologic and metabolic conditions. FDA leadership instability could disproportionately impact cell and gene therapy for rare disease through reduced approval of edge cases. Portfolio includes oncology-focused companies like UroGen Pharma developing innovative solutions for urothelial and specialty cancers, and Immatics developing novel PRAME immunotherapies for cancer patients. The sector represents 16% of disease area exposure. The portfolio has exposure to gene and RNA therapies, with companies like Stoke Therapeutics restoring protein expression by harnessing the body's potential with RNA medicine. This modality represents 15% of the portfolio's exposure by treatment type. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| No pitches found. | |||||||||
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| Peter Chernin | TCG Crossover | $3.0B | $90.3M | 2.99% | 4,615,144 | +1,964,994 | +74.15% | 3.5578% |
| Paul Tudor Jones | Tudor Investment Corp | $53.4B | $2.9M | 0.01% | 147,621 | +147,621 | +100.00% | 0.1138% |
| Steven A. Cohen | Point72 Asset Management | $86.8B | $6.4M | 0.01% | 329,345 | -1,388,462 | -80.83% | 0.2539% |
| Robert Pohly | Samlyn Capital | $6.3B | $29.2M | 0.47% | 1,493,075 | +1,493,075 | +100.00% | 1.1510% |
| Cliff Asness | AQR Capital Management | $190.6B | $1.4M | 0.00% | 70,659 | -71,216 | -50.20% | 0.0545% |
| Dmitry Balyasny | Balyasny Asset Management | $76.6B | $8.5M | 0.01% | 432,986 | -55,512 | -11.36% | 0.3338% |
| Israel Englander | Millennium Management LLC | $233.2B | $17.7M | 0.01% | 904,389 | +490,449 | +118.48% | 0.6972% |
| Terrence Murphy | Clearbridge Investments | $124.9B | $8.0M | 0.01% | 407,794 | +407,794 | +100.00% | 0.3144% |
| Mark Bussard | Rock Springs Capital | $1.9B | $17.9M | 0.92% | 912,955 | +88,894 | +10.79% | 0.7038% |
| Brian Ashford-Russell | Polar Capital Holdings | $25.8B | $24.8M | 0.10% | 1,269,131 | +739,743 | +139.74% | 0.9784% |
| Joseph Edelman | Perceptive Advisors | $5.6B | $68.0M | 1.22% | 3,478,944 | +2,938,500 | +543.72% | 2.6819% |
| Jayson Yuan | Palo Alto Investors LP | $718.4M | $28.8M | 4.01% | 1,472,197 | +209,523 | +16.59% | 1.1349% |
| Tom Steyer | Farallon Capital Management | $21.2B | $195,600 | 0.00% | 10,000 | -10,000 | -50.00% | 0.0077% |